1. Home
  2. PPCB vs GOVX Comparison

PPCB vs GOVX Comparison

Compare PPCB & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PPCB

Propanc Biopharma Inc.

N/A

Current Price

$0.22

Market Cap

5.7M

Sector

N/A

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$2.89

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPCB
GOVX
Founded
2007
2001
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
5.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PPCB
GOVX
Price
$0.22
$2.89
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$103.00
AVG Volume (30 Days)
565.5K
206.1K
Earning Date
02-15-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,353,560.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.52
52 Week Low
$0.24
$2.61
52 Week High
$145.46
$51.75

Technical Indicators

Market Signals
Indicator
PPCB
GOVX
Relative Strength Index (RSI) 27.01 66.29
Support Level $0.24 $2.66
Resistance Level $0.40 $3.42
Average True Range (ATR) 0.06 0.43
MACD 0.01 -0.02
Stochastic Oscillator 7.08 9.19

Price Performance

Historical Comparison
PPCB
GOVX

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: